Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy

被引：1
|
作者：
Yang, J. C-H. [1 ]
Ramalingam, S. S. [2 ]
Kim, T. M. [3 ]
Kim, S-W. [4 ]
Riely, G. J. [5 ]
Mekhail, T. [6 ]
Nguyen, D. [7 ]
Campelo, M. R. Garcia [8 ]
Felip, E. [9 ]
Bazhenova, L. [10 ]
Jin, S. [11 ,12 ]
Griffin, C. [13 ]
Bunn, V. [12 ,14 ]
Lin, J. [12 ,15 ]
Churchill, E. N. [12 ,16 ]
Mehta, M. [11 ,12 ]
Janne, P. A. [17 ]
Zhou, C. [18 ]
机构：
[1] Natl Taiwan Univ, Ctr Canc, Dept Med Oncol, Taipei, Taiwan
[2] Emory Univ, Winship Canc Inst, Hematol & Med Oncol Dept, Atlanta, GA USA
[3] Seoul Natl Univ Hosp, Dept Hematooncol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[5] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[6] AdventHlth Orlando, Thorac Canc Program, Orlando, FL USA
[7] Pacific Shores Med Grp, Hematol Oncol, Long Beach, CA USA
[8] Univ Hosp A Coruna, CHUAC, Dept Med Oncol, La Coruna, Spain
[9] Vall Hebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain
[10] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[11] Millennium Pharmaceut Inc, Clin Sci, Oncol, Cambridge, MA USA
[12] Takeda Pharmaceut Co Ltd, Cambridge, MA USA
[13] Millennium Pharmaceut Inc, Global Patient Safety Evaluat, Cambridge, MA USA
[14] Millennium Pharmaceut Inc, Stat, Cambridge, MA USA
[15] Millennium Pharmaceut Inc, Oncol Stat, Cambridge, MA USA
[16] Millennium Pharmaceut Inc, Global Med Affairs Oncol, Cambridge, MA USA
[17] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[18] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1836
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1231P
引用
收藏
页码：S975 / S975
页数：1
相关论文
共 50 条
  • [31] EGFR exon20 Insertion Patients Treated with First-Line Chemotherapy in Non-Small Cell Lung Cancer
    Zhao, C.
    Li, X.
    Su, C.
    Chen, X.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S507 - S507
  • [32] Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
    Gao, X.
    Wei, X-W.
    Wu, Y-L.
    Zhou, Q.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)
    Choi, Dae-Ho
    Jung, Hyun Ae
    Park, Sehhoon
    Sun, Jong -Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Lee, Se-Hoon
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (12) : 2448 - 2459
  • [34] Pembrolizumab and chemotherapy in non-small cell lung cancer with EGFR ex20ins mutation: A case report
    Zhang, Meng
    Nie, Ligong
    Cheng, Yuan
    THORACIC CANCER, 2021, 12 (20) : 2803 - 2806
  • [35] The landscape of EGFR exon 20 insertion mutations in Chinese patients with non-small cell lung cancer.
    Xu, Shun
    Fu, Zhichao
    CANCER RESEARCH, 2022, 82 (12)
  • [36] Understanding the diagnostic and treatment landscape in EGFRm advanced non-small cell lung cancer (aNSCLC) patients with exon 20 insertion mutations (Ex20ins)
    Bailey, H.
    Nasirova, F.
    Sermon, J.
    Rodrigues, B.
    Khela, K.
    Hall, J.
    Last, M. J.
    Penton, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S975 - S976
  • [37] Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer
    Gao, Xin
    Wei, Xue-Wu
    Zheng, Ming-Ying
    Chen, Zhi-Hong
    Zhang, Xu-Chao
    Zhong, Wen-Zhao
    Yang, Jin-Ji
    Wu, Yi-Long
    Zhou, Qing
    JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 5822 - +
  • [38] Epidermal growth factor receptor (EGFR) testing and treatment patterns associated with diagnosis of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) in the US
    Piotrowska, Z.
    Lin, M.
    Yin, Y.
    Curran, E.
    Crossland, V.
    Wu, Y.
    Ou, S-H. I.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1011 - S1011
  • [39] Response to Mobocertinib in a patient with advanced Non-Small Cell Lung Cancer harboring EGFR exon 20 insertion after several therapies including Amivantamab
    de la Fuente, Elena Corral
    Garcia, Maria Eugenia Olmedo
    Martin, Inmaculada Orejana
    Berlinches, Amparo Benito
    Rueda, Ana Gomez
    Alfranca, Yolanda Lage
    Garrido, Pilar
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2022, 5
  • [40] Comprehensive analysis of next generation sequencing and ARMS-PCR for detecting EGFR exon 20 insertion (ex20ins) mutations in Chinese non-small cell lung cancer patients
    Xu, Yuyin
    Jia, Liqing
    Jiang, Ling
    Wang, Haochen
    Jiang, Lin
    Feng, Xu
    Wei, Ran
    Yao, Qianlan
    Ren, Min
    Xue, Tian
    Li, Yuan
    Zhu, Xiaoli
    Zhou, Xiaoyan
    Bai, Qianming
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (05) : 986 - 997
12345